Health · Medical Research · 3 hrs ago
Engineered Stem Cell Infusion Linked to Fewer Fractures in Small Osteoporosis Trial
Researchers in Spain tested an engineered stem cell treatment in 10 women over 50 with advanced osteoporosis.
The treatment used each patient’s own mesenchymal stem cells, which can develop into cells that build and repair bone, and a special sugar coating intended to help them reach bone marrow.
After one infusion, average fractures fell from eight a year to 0.5 during the next two years.
Four months after treatment, biopsies showed that the average area occupied by bone tissue had increased by about 70 percent.
The findings suggest the treatment may do more than reduce fractures, but they do not prove that it can reverse bone loss.
Researchers did not track the infused cells in patients, so it is unclear whether they reached bone marrow as intended; participants also reported less bone pain and disability two years later.
A first-in-human trial found fewer fragility fractures among 10 women with advanced osteoporosis after they received an infusion of their own engineered stem cells.
The patients’ average fractures fell from eight per year in the two years before treatment to 0.5 per year in the two years afterward.
Four months after the infusion, the average area occupied by bone tissue had increased by around 70 percent.
Researchers did not track the infused cells in the patients, so the trial did not establish whether they reached the bone marrow.
- Who
- 10 women older than 50 with advanced osteoporosis took part in the trial.
- What
- They received a single infusion of their own engineered mesenchymal stem cells, enveloped in a special sugar.
- When
- The trial was reported on November 15, 2026. Patients were followed for two years after the infusion.
- Where
- Researchers in Spain conducted the trial.
- Why
- The treatment was designed to help stem cells reach bone marrow and potentially support bone growth.
This story does not have two clearly opposing sides.
Participants had an average of eight fractures per year.
Each participant received a single infusion of their own engineered stem cells.
Bone biopsies showed that average bone tissue area had increased by around 70 percent.
Participants had an average of 0.5 fractures per year, and reported less bone pain and disability.
- Participants
- 10 women older than 50 with advanced osteoporosis
- Treatment
- A single infusion of each patient’s own engineered mesenchymal stem cells
- Fractures before treatment
- Average of eight per year in the two years before infusion
- Fractures after treatment
- Average of 0.5 per year in the two years after infusion
- Bone tissue area
- Increased by around 70 percent at four months
- Bone pain
- Decreased by 34 percent two years after infusion
What people are saying
quite remarkable
showed an almost 100 percent efficacy sustained for several years – and no side effects